|
Name: Xuetao Pei, See AMMS
Title: Director, Professor
Academic Degree: Ph.D., M.D.
Address: Beijing Institute of Transfusion Medicine, AMMS Stem Cell & Regenerative Medicine
Education:
1987,8 - 1990,7 Beijing Institute of Radiation Medicine, Ph.D., M.D.
1984,8 - 1987,7 Beijing Institute of Radiation Medicine, MMS
1978,8 - 1983,8 The Third Medical College, Chongqing, China, BMS
Work and Research Experience:
2000— Director, Professor of Beijing Institute of Transfusion Medicine, working on Stem Cell Biology and Regenerative Medicine.
1997—1999 Professor of Beijing Institute of Radiation Medicine, working on the Engineering of Hematopoietic Cells, Cell therapy and gene therapy.
1992 -1997 Associate Professor of Beijing Institute of Radiation Medicine, working on the fields of the isolation, characterization, expansion and orderly differentiation of CD34+ hematopoietic progenitor cells and their subsets.
1993 - 1994 As a Visiting Scholar in Paterson Institute for Cancer Research in Manchester, UK, working on the fields of the sorting and characterization of CD34+CD38+ and CD34+CD38- subsets by FACS Vantage directed by Testa NG and Dexter TM.
1987 - 1992 Graduate student for Ph.D., M.D. and Assistant Researcher of Beijing Institute of Radiation Medicine, working on the fields of the characterization and mechanism of a low molecular weight tumor suppressor (Dibutyl Phthalate, DBP) and its preliminary application in purged autologous bone marrow transplantation in the treatment of leukemia and lymphoma.
Several research awards have been obtained, including first and second Prizes awarded by ministry of military sciences and Beijing government; more than 200 publications in scientific journals; 9 books for authors or co-authors. 32 patents have been applied for, and 3 patents were authorized. The Prize of Paul H. Fraisse Award Best Scientific Contribution(J was awarded in the 2nd World Congress on Regenerative Medicine in Leipzig Germany, May 2005.
As the Invited Speaker, gave the lectures in more then 30 important Symposiums on Stem Cell and Regenerative Medicine Research, including the 2nd World Congress on Regenerative Medicine in Leipzig Germany, the 4th World Life Science Forum BioVision in Lyon France, the 3rd Annual Global Summit: Stem Cell Research: Clinical Trials and Commercial Applications in Singapore, the 29th World Congress of the International Society of Hematology in Seoul Korea, etc.
Concurrent Posts:
1 Chief Scientist(JKey Project of State High-tech Project (863 Program) tem Cell and Tissue Engineering for Regenerative Medicine
2 Director of Beijing Institute of Transfusion Medicine
3 Director of AMMS Stem Cell and Regenerative Medicine Center
4 Vice-President and Secretary General of Chinese Society for Experimental Hematology
5 Vice-President of Beijing Society for Stem Cell Research
6 Deputy Secretary General of Chinese Blood Biotechnology Association
7 Board Member of International Association of Radiopathology (IAR)
8 Cord Member of Asia Hematology Association (AHA)
9 ASH Member
10 ISAC Member
11 Deputy Editor-in-Chief of Chinese Journal of Experimental Hematology
12 Deputy Editor-in-Chief of Chinese Journal of Transfusion Medicine
13 Deputy Editor-in-Chief of Stem Cell and Cellular Therapy
14 International Editor of International Journal of Hematology
15 Special Editor of Chinese Science Bulletin
16 Editor of Progress in Natural Science
Publications:
More than 200 papers published including:
1. Effects of human fetal liver extract on the growth of HL-60 cells. Exp Hematol,1989,17:304
2. Preferential suppression of low molecular weight natural tumor suppressor of human fetal liver origin on the growth of leukemic cells in vitro. Exp Hematol,1990,18:927
3. A new pharmacological activity of Dibutyl Phthalate(DBP) on selective elimination of tumor cells from bone marrow. Leuk Res,1993,17:557
4. Comparison of purity and enrichment of CD34+ cells from bone marrow, umbilical cord and peripheral blood(primed for apheresis) using five separation systems. Stem Cells,1995,13:524
5. Dibutyl Phthalate(DBP) purged autologous bone marrow transplantation in the treatment of leukemia. Leuk Res,1996,20:343
6. Who is hematopoietic stem cell: CD34+ or CD34-? Int J Hematol, 1999,70:213
7. Stem cell engineering: the new generation of cellular therapeutics. Int J Hematol 2002,76JJSuppl 1(J155)
8. In vitro induced dopaminergic differentiation of expanded rat mesencephalic neural stem cell. Chinese Science Bulletin, 2003,48:1759
9. Radioprotective effect of FLT3 ligand expression regulated by Egr-1 regulated element on radiation injury of SCID mice. Exp Hematol, 2003,31:191
10. Induce umbilical cord blood mesenchymal stem cells into neuron-like cells in vitro. Int J Hematol, 2003,74:256
11. Inducing dopaminergic differentiation of expanded rat mesencephalic neural stem cells by ascorbic acid in vitro. Progress in Natural Science, 2004,14:26
12. Differentiation of bone marrow derived Thy-1+ 2M- cells into hepatocytes induced by coculture with transgenic CFSCs. Chinese Science Bulletin, 2004,49:889
13. Differentiation potential of bone marrow mesenchymal stem cells into retina in normal and laser-injured rat eye. Science in China Ser. C Life Sciences, 2004, 47: 241
14. Modification of the Brain-Derived Neurotrophic Factor Gene: A Portal to Transform Mesenchymal Stem Cells into Advantageous Engineering Cells for Neuroregeneration and Neuroprotection. Exp Neurol, 2004, 190:396
15. Induction of Umbilical Blood Derived 2M-c-met+ cell into Hepatocyte-like cells by coculture with CFSC/HGF cells. Liver transplantation, 2005,11(J635)
16. Spindlin1, a novel nuclear protein with a role in the transformation of NIH3T3 cells. Biochem Biophys Res Commun. 2005,335:343
17. Humanin delayed apoptosis induced by serum deprivation in K562 cells by down-regulation of p38. Apoptosis, 2005, in press
|
